Kraus Al 4
4 · Cytosorbents Corp · Filed Nov 12, 2020
Insider Transaction Report
Form 4
Kraus Al
Director
Transactions
- Sale
Common Stock
2020-11-10$8.00/sh−8,000$64,000→ 125,046 total - Exercise/Conversion
Common Stock
2020-11-10$3.45/sh+8,000$27,600→ 133,046 total - Exercise/Conversion
Stock Option (right to buy)
2020-11-10−8,000→ 0 totalExercise: $3.45Exp: 2021-01-06→ Common Stock (8,000 underlying)
Footnotes (3)
- [F1]These shares were sold in multiple transactions and multiple lots for the same price for this sale have been combined.
- [F2]Includes: (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 55,000 RSUs granted on April 8, 2015, (b) 5,000 RSUs granted on June 7, 2016, (c) 6,000 RSUs granted on February 24, 2017 and (d) 3,300 RSUs granted on March 15, 2018; and (ii) 55,746 shares of common stock owned by the reporting person.
- [F3]These options were originally granted to Mr. Kraus on January 6, 2011 as compensation for services rendered. The grant became fully vested on January 6, 2020.